Recall Z-1928-2021— Quidel Corporation

Class I · Terminated

Class I FDA medical device recall by Quidel Corporation, initiated 2021-04-27, terminated 2022-09-08. FDA's recall record names no specific 510(k) clearance for this event. Product: Lyra SARS-CoV-2 Assay (M120) in vitro diagnostic test reagent. Reason: In rare situations patients infected with high viral load of SARS CoV 2 may have samples that generate Ct values less than or equal to (d) 5 when certain amplification and detection platforms (thermocyclers) are used. These specimens would be falsely interpreted as negative if target amplification occurs prior to a cycle threshold (Ct) value of 5. There have been no formal complaints of False Negative results with Ct values <5 from Lyra SARS-CoV-2 Assay users..

Recalling firm
Quidel Corporation
Classification
Class I
Status
Terminated
Initiated
2021-04-27
Terminated
2022-09-08
Firm location
Athens, OH, United States

Product description

Lyra SARS-CoV-2 Assay (M120) in vitro diagnostic test reagent

Reason for recall

In rare situations patients infected with high viral load of SARS CoV 2 may have samples that generate Ct values less than or equal to (d) 5 when certain amplification and detection platforms (thermocyclers) are used. These specimens would be falsely interpreted as negative if target amplification occurs prior to a cycle threshold (Ct) value of 5. There have been no formal complaints of False Negative results with Ct values <5 from Lyra SARS-CoV-2 Assay users.

Data sourced from openFDA. This site is unofficial and independent of the FDA.